Loading...
XNASSNY
Market cap119bUSD
Dec 20, Last price  
47.71USD
1D
0.44%
1Q
-17.21%
Jan 2017
17.98%
Name

Sanofi SA

Chart & Performance

D1W1MN
XNAS:SNY chart
P/E
10.64
P/S
1.33
EPS
4.31
Div Yield, %
7.45%
Shrs. gr., 5y
0.02%
Rev. gr., 5y
3.84%
Revenues
46.03b
+1.42%
15,721,436,16028,491,240,95029,489,294,80029,207,000,00028,817,000,00030,749,000,00034,036,000,00035,058,000,00035,957,000,00031,291,000,00031,999,000,00034,861,000,00034,696,000,00036,221,000,00035,677,000,00037,631,000,00037,369,000,00039,175,000,00045,389,000,00046,033,000,000
Net income
5.40b
-35.49%
1,984,359,2002,255,996,3204,005,907,0305,263,000,0003,851,000,0005,265,000,0005,467,000,0005,646,000,0004,888,000,0003,716,000,0004,390,000,0004,287,000,0004,709,000,0008,416,000,0004,306,000,0002,754,000,00012,294,000,0006,223,000,0008,371,000,0005,400,000,000
CFO
10.26b
-2.55%
4,046,174,8006,393,115,3206,604,026,0407,106,000,0008,523,000,0008,515,000,0009,859,000,0009,319,000,0008,171,000,0006,954,000,0007,690,000,0008,920,000,0008,184,000,0007,379,000,0005,547,000,0007,715,000,0007,418,000,00010,522,000,00010,526,000,00010,258,000,000
Dividend
May 09, 20242.19782 USD/sh
Earnings
Apr 30, 2025

Profile

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
IPO date
Jul 01, 2002
Employees
91,573
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
46,033,000
1.42%
45,389,000
15.86%
39,175,000
4.83%
Cost of revenue
20,964,000
20,401,000
17,947,000
Unusual Expense (Income)
NOPBT
25,069,000
24,988,000
21,228,000
NOPBT Margin
54.46%
55.05%
54.19%
Operating Taxes
1,602,000
2,006,000
1,558,000
Tax Rate
6.39%
8.03%
7.34%
NOPAT
23,467,000
22,982,000
19,670,000
Net income
5,400,000
-35.49%
8,371,000
34.52%
6,223,000
-49.38%
Dividends
(4,454,000)
(4,168,000)
(4,008,000)
Dividend yield
3.95%
1.85%
1.80%
Proceeds from repurchase of equity
(398,000)
(309,000)
(196,000)
BB yield
0.35%
0.14%
0.09%
Debt
Debt current
2,320,000
4,451,000
3,452,000
Long-term debt
18,132,000
18,942,000
21,070,000
Deferred revenue
7,801,000
8,469,000
Other long-term liabilities
9,958,000
1,193,000
868,000
Net debt
8,485,000
7,228,000
10,948,000
Cash flow
Cash from operating activities
10,258,000
10,526,000
10,522,000
CAPEX
(3,253,000)
(2,201,000)
(2,043,000)
Cash from investing activities
(6,200,000)
(2,075,000)
(7,298,000)
Cash from financing activities
(8,052,000)
(5,821,000)
(7,056,000)
FCF
23,857,000
23,744,000
19,289,000
Balance
Cash
8,710,000
13,400,000
11,152,000
Long term investments
3,257,000
2,765,000
2,422,000
Excess cash
9,665,350
13,895,550
11,615,250
Stockholders' equity
75,224,000
137,809,000
128,046,000
Invested Capital
93,067,650
90,468,450
88,429,750
ROIC
25.57%
25.69%
23.31%
ROCE
23.97%
23.53%
20.88%
EV
Common stock shares outstanding
1,256,400
2,513,800
2,515,800
Price
89.76
-0.09%
89.84
1.42%
88.58
12.55%
Market cap
112,774,464
-50.06%
225,839,782
1.34%
222,849,564
12.36%
EV
121,572,464
233,435,782
234,147,564
EBITDA
28,845,000
28,408,000
24,579,000
EV/EBITDA
4.21
8.22
9.53
Interest
1,094,000
472,000
403,000
Interest/NOPBT
4.36%
1.89%
1.90%